Cancer immune exclusion: breaking the barricade for a successful immunotherapy

Frontiers in Oncology

Oncology

Rosalia Inés Cordo Russo¹  María Florencia Mercogliano¹  Florencia Luciana Mauro¹  Roxana Schillaci¹  Sofia Bruni¹ 

[1] Laboratorio de Mecanismos Moleculares de Carcinogénesis. Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina;

关键词: tumor microenvironment;    immune exclusion;    physical barrier;    myeloid cells;    extracellular matrix;    tumor infiltrating lymphocytes (TILs);    tumor-associated vasculature;    tumor-associated macrophage (TAMs);   

DOI  :  10.3389/fonc.2023.1135456

 received in 2022-12-31, accepted in 2023-05-10,  发布年份 2023

来源: Frontiers

【 摘 要 】

Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving positive clinical resolutions rests upon the access of immune cells to the tumor. In this review, we focus on how the tumor microenvironment architecture, including stromal cells, immunosuppressive cells and extracellular matrix, protects tumor cells from an immune attack leading to immunotherapy resistance, and on the available strategies to tackle immune evasion.

【 授权许可】

Unknown   
Copyright © 2023 Bruni, Mercogliano, Mauro, Cordo Russo and Schillaci